Phase III Vaccine Combo Extends Melanoma PFS to 19.4 Months vs 11.0 With Pembrolizumab Alone
Updated
Updated · Nature.com · Sep 18
Phase III Vaccine Combo Extends Melanoma PFS to 19.4 Months vs 11.0 With Pembrolizumab Alone
2 articles · Updated · Nature.com · Sep 18
Summary
19.4 months of median progression-free survival was reported with IDO/PD-L1 peptide vaccination plus pembrolizumab in advanced melanoma, versus 11.0 months with pembrolizumab alone, even though the trial narrowly missed its prespecified primary-endpoint significance threshold.
24.8 months versus 11.0 months in the anti-PD-1-naive subgroup—371 of 407 randomized patients—provided the strongest signal, while PD-L1-negative patients showed 16.6 months versus 3.0 months.
No increase in grade 3/4 treatment-related or serious adverse events was seen, supporting the regimen's translational potential alongside the efficacy signal.
The report argues the findings back immune modulatory vaccines as a way to target suppressive tumor microenvironments, not just tumor cells, by engaging anti-regulatory T-cell responses.
That mechanism could broaden beyond melanoma, with related IDO/PD-L1 mRNA and checkpoint-combination programs already in development and possible relevance for fibrosis-rich or immune-excluded tumors.